Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Other Non-Current Assets data on record, last reported at $1.3 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 36.59% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, up 36.59%, while the annual FY2024 figure was $951000.0, 15.77% down from the prior year.
  • Other Non-Current Assets reached $1.3 million in Q3 2025 per TNXP's latest filing, up from $931000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.3 million in Q3 2025 and bottomed at $292000.0 in Q2 2023.
  • Average Other Non-Current Assets over 3 years is $892727.3, with a median of $951000.0 recorded in 2024.
  • The widest YoY moves for Other Non-Current Assets: up 229.11% in 2024, down 15.77% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $1.1 million in 2023, then decreased by 15.77% to $951000.0 in 2024, then skyrocketed by 36.59% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.3 million in Q3 2025, $931000.0 in Q2 2025, and $910000.0 in Q1 2025.